BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25531982)

  • 1. High-dose weekly liposomal amphotericin b antifungal prophylaxis in patients undergoing liver transplantation: a prospective phase II trial.
    Giannella M; Ercolani G; Cristini F; Morelli M; Bartoletti M; Bertuzzo V; Tedeschi S; Faenza S; Puggioli C; Lewis RE; Pinna AD; Viale P
    Transplantation; 2015 Apr; 99(4):848-54. PubMed ID: 25531982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose amphotericin for prevention of serious fungal infection following liver transplantation.
    Shah T; Lai WK; Gow P; Leeming J; Mutimer D
    Transpl Infect Dis; 2005; 7(3-4):126-32. PubMed ID: 16390401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
    Luu Tran H; Mahmoudjafari Z; Rockey M; Henry D; Grauer D; Aljitawi O; Abhyankar S; Ganguly S; Lin T; McGuirk J
    J Oncol Pharm Pract; 2016 Apr; 22(2):228-34. PubMed ID: 25471252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
    Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
    Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.
    Cordonnier C; Mohty M; Faucher C; Pautas C; Robin M; Vey N; Monchecourt F; Mahi L; Ribaud P
    Int J Antimicrob Agents; 2008 Feb; 31(2):135-41. PubMed ID: 18162375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients.
    Bochennek K; Tramsen L; Schedler N; Becker M; Klingebiel T; Groll AH; Lehrnbecher T
    Clin Microbiol Infect; 2011 Dec; 17(12):1868-74. PubMed ID: 21895857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients.
    Sun HY; Cacciarelli TV; Singh N
    Transplantation; 2013 Sep; 96(6):573-8. PubMed ID: 23842191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes associated with amphotericin B lipid complex (ABLC) prophylaxis in high-risk liver transplant patients.
    Saliba F; Delvart V; Ichaï P; Kassis N; Botterel F; Mihaila L; Azoulay D; Adam R; Castaing D; Bretagne S; Samuel D
    Med Mycol; 2013 Feb; 51(2):155-63. PubMed ID: 22800082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.
    Jansen J; Akard LP; Wack MF; Thompson JM; Dugan MJ; Leslie JK; Mattison R
    Mycoses; 2006 Sep; 49(5):397-404. PubMed ID: 16922792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.
    Annino L; Chierichini A; Anaclerico B; Finolezzi E; Norata M; Cortese S; Cassetta MI; Fallani S; Novelli A; Girmenia C
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2596-602. PubMed ID: 23529741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B.
    Krüger WH; Rüssmann B; de Wit M; Kröger N; Renges H; Sobottka I; Zander AR
    Acta Haematol; 2005; 113(2):104-8. PubMed ID: 15802888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation.
    Singhal S; Ellis RW; Jones SG; Miller SJ; Fisher NC; Hastings JG; Mutimer DJ
    Liver Transpl; 2000 Sep; 6(5):588-95. PubMed ID: 10980058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation.
    El-Cheikh J; Faucher C; Fürst S; Duran S; Berger P; Vey N; Stoppa AM; Bouabdallah R; Gastaut JA; Viens P; Blaise D; Mohty M
    Bone Marrow Transplant; 2007 Mar; 39(5):301-6. PubMed ID: 17262059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation.
    Chaftari AM; Hachem RY; Ramos E; Kassis C; Campo M; Jiang Y; Prince RA; Wang W; Raad II
    Transplantation; 2012 Aug; 94(3):302-8. PubMed ID: 22814329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.
    Wolff SN; Fay J; Stevens D; Herzig RH; Pohlman B; Bolwell B; Lynch J; Ericson S; Freytes CO; LeMaistre F; Collins R; Pineiro L; Greer J; Stein R; Goodman SA; Dummer S
    Bone Marrow Transplant; 2000 Apr; 25(8):853-9. PubMed ID: 10808206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients.
    Castroagudín JF; Pontón C; Bustamante M; Otero E; Martínez J; Tomé S; Conde R; Segade FR; Delgado M; Brage A; Galbán C; Varo E
    Transplant Proc; 2005 Nov; 37(9):3965-7. PubMed ID: 16386598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: a prospective, randomized, open-label, placebo-controlled pilot study.
    Arrieta AC; Shea K; Dhar V; Cleary JP; Kukreja S; Morris M; Vargas-Shiraishi OM; Ashouri N; Singh J
    Clin Ther; 2010 Feb; 32(2):265-71. PubMed ID: 20206784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation.
    Kolve H; Ahlke E; Fegeler W; Ritter J; Jürgens H; Groll AH
    J Antimicrob Chemother; 2009 Aug; 64(2):383-7. PubMed ID: 19491205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
    Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
    N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
    Rieger CT; Dittmer M; Ostermann H
    Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.